Eli Lilly and Company reported positive results from its Phase 3b TOGETHER-PsO study of Taltz (ixekizumab) and Zepbound (tirzepatide) in adults with both psoriasis and obesity. Compared with Taltz alone, the combination produced broader biological effects.
By week 36, the combination had led to greater changes in proteins and genes associated with the conditions, as well as improved skin clearance and weight loss. The findings support Lilly’s strategy of targeting interconnected metabolic and inflammatory diseases and could expand the market for both drugs.
The announcement came amid bullish analyst sentiment. Cantor Fitzgerald raised its price targets for Eli Lilly, citing strong demand for its obesity drugs and a robust pipeline. The content did not specify a market reaction to the study data; it also noted strong quarterly performance.